80% of PKU centers of excellence in the U.S. had written prescriptions for one or more patientsSephience contributed $92 million of revenue in the fourth quarter and $111 million worldwide since launch in 2025. Pauwels said fourth-quarter Sephience revenue was approximately $92 million, including $81 million in the U.S. and $11 million ex-U.S.For the fourth quarter, PTC reported total net product and royalty revenue of $263 million . Full-year 2025 total net product and royalty revenue was $831 million , wh ...

Core Insights - PTC Therapeutics reported a revenue of $164.68 million for Q4 2025, marking a year-over-year decline of 22.8% and significantly missing the Zacks Consensus Estimate of $304.72 million by 45.96% [1] - The company experienced an EPS of -$1.67, which is a substantial drop from -$0.24 a year ago, resulting in an EPS surprise of -700.58% compared to the consensus estimate of -$0.21 [1] Revenue Breakdown - Net product revenue reached $183.99 million, exceeding the four-analyst average estimate of $174.53 million, reflecting an 18.9% year-over-year increase [4] - Royalty revenue was reported at $79.39 million, surpassing the average estimate of $70.77 million, with a year-over-year change of 36.5% [4] - Net product revenue from Translarna was $39 million, slightly below the average estimate of $40.42 million, showing a significant decline of 58.4% year-over-year [4] - Net product revenue from Emflaza was $27.1 million, which is lower than the estimated $29.58 million, representing a 46.3% decrease compared to the previous year [4] - Collaboration and license revenue was reported at -$0.07 million, a stark contrast to the average estimate of $118.82 million [4] Stock Performance - PTC Therapeutics shares have returned -8.8% over the past month, compared to a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.67 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -700.58%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.19 per share when it actually produced earnings of $0.2, delivering a surprise of +116.81%.Over the last four quarters ...

PTC Therapeutics (NasdaqGS:PTCT) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsEllen Cavaleri - Head of Investor RelationsEric Pauwels - Chief Business OfficerJarwei Fang - VP of Large-Cap Biotechnology and Pharma Equity ResearchJoe Heidt - Equity Research AssociateMatthew Klein - CEOPierre Gravier - CFOTazeen Ahmad - Managing DirectorConference Call ParticipantsBen Burnett - Executive Director and Senior Equity AnalystBrian Cheng - Executive Director and Senior Biotech AnalystElli ...

PTC Therapeutics (NasdaqGS:PTCT) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsEllen Cavaleri - Head of Investor RelationsEric Pauwels - Chief Business OfficerJarwei Fang - VP of Large-Cap Biotechnology and Pharma Equity ResearchJoe Heidt - Equity Research AssociateMatthew Klein - CEOPierre Gravier - CFOTazeen Ahmad - Managing DirectorConference Call ParticipantsBen Burnett - Executive Director and Senior Equity AnalystBrian Cheng - Executive Director and Senior Biotech AnalystElli ...

PTC Therapeutics (NasdaqGS:PTCT) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Speaker12Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics' fourth quarter and full year 2025 earnings conference call. All participants are in a listen-only mode. After the presentation, there will be a question-and-answer session. Today's conference is being recorded. I would now like to turn the conference over to Ellen Cavaleri, Head of Investor Relations. Please, please go ahead.Speaker2Good ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35969 PTC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...

measures. In particular, the non-GAAP R&D and SG&A expense financial measures exclude non-cash, stock- based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in accordance with GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater tran ...

Wall Street analysts expect PTC Therapeutics (PTCT) to post quarterly loss of -$0.21 per share in its upcoming report, which indicates a year-over-year increase of 12.5%. Revenues are expected to be $304.72 million, up 42.9% from the year-ago quarter.The current level reflects an upward revision of 15.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a ...

Regulatory Update - PTC Therapeutics has withdrawn the New Drug Application (NDA) resubmission for Translarna (ataluren) for treating nonsense mutation Duchenne muscular dystrophy (DMD) due to FDA feedback indicating the data is unlikely to meet the effectiveness threshold for approval [1] - The CEO of PTC Therapeutics expressed disappointment over the inability to achieve FDA approval after over two decades of development efforts for a therapy aimed at boys and young men with nonsense mutation DMD [1] Product Information - Translarna (ataluren) is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation, which halts essential protein synthesis [1] - Duchenne muscular dystrophy is a rare and fatal genetic disorder primarily affecting males, leading to progressive muscle weakness and premature death due to heart and respiratory failure [1] Company Overview - PTC Therapeutics is a global biopharmaceutical company focused on discovering, developing, and commercializing clinically differentiated medicines for rare disorders [1] - The company aims to provide access to best-in-class treatments for patients with unmet medical needs through a robust and diversified pipeline of transformative medicines [1]